🌍 #Macro
"VANCOUVER, British Columbia, July 13, 2026 (GLOBE NEWSWIRE) — Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local,…"
"VANCOUVER, British Columbia, July 13, 2026 (GLOBE NEWSWIRE) — Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local,…"
Eupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of Growth
financialpost.com
July 13, 2026 at 9:25 PM
NEWS: ( NASDAQ: #EPRX ) Eupraxia's DiffuSphere(TM) Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months
#StockMarket #News
#StockMarket #News
November 20, 2024 at 5:10 PM
Eupraxia Pharmaceuticals Reveals Compelling Financial Results for Q4 2024#Canada#Victoria#EP-104GI#Eupraxia#DiffuSphere
Eupraxia Pharmaceuticals Reveals Compelling Financial Results for Q4 2024
Eupraxia Pharmaceuticals Inc. announces its Q4 2024 financial results highlighting significant advancements in clinical trials and improved financial health.
third-news.com
March 20, 2025 at 9:37 PM
Eupraxia Pharmaceuticals Reveals Compelling Financial Results for Q4 2024#Canada#Victoria#EP-104GI#Eupraxia#DiffuSphere
#EPRX Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results
https://www.stocktitan.net/news/EPRX/eupraxia-pharmaceuticals-reports-fourth-quarter-2025-financial-h870xllsj07b.html
https://www.stocktitan.net/news/EPRX/eupraxia-pharmaceuticals-reports-fourth-quarter-2025-financial-h870xllsj07b.html
Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results
Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for
www.stocktitan.net
March 13, 2026 at 1:04 AM
#EPRX Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results
https://www.stocktitan.net/news/EPRX/eupraxia-pharmaceuticals-reports-fourth-quarter-2025-financial-h870xllsj07b.html
https://www.stocktitan.net/news/EPRX/eupraxia-pharmaceuticals-reports-fourth-quarter-2025-financial-h870xllsj07b.html
#EPRX Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months
https://www.stocktitan.net/news/EPRX/eupraxia-s-diffu-sphere-tm-technology-demonstrates-targeted-drug-n5z6fi5zfthb.html
https://www.stocktitan.net/news/EPRX/eupraxia-s-diffu-sphere-tm-technology-demonstrates-targeted-drug-n5z6fi5zfthb.html
November 20, 2024 at 12:00 PM
#EPRX Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months
https://www.stocktitan.net/news/EPRX/eupraxia-s-diffu-sphere-tm-technology-demonstrates-targeted-drug-n5z6fi5zfthb.html
https://www.stocktitan.net/news/EPRX/eupraxia-s-diffu-sphere-tm-technology-demonstrates-targeted-drug-n5z6fi5zfthb.html
#EPRX New #Pharmacokinetic data shows their diffusphere technology effectively targets drug release, minimizing systemic exposure. A significant step forward in the eosinophilic esophagitis program.
#biotech #pharma
#biotech #pharma
November 20, 2024 at 5:30 PM
#EPRX New #Pharmacokinetic data shows their diffusphere technology effectively targets drug release, minimizing systemic exposure. A significant step forward in the eosinophilic esophagitis program.
#biotech #pharma
#biotech #pharma
📰 #Finance
"VANCOUVER, British Columbia, June 19, 2026 (GLOBE NEWSWIRE) — Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local,…"
"VANCOUVER, British Columbia, June 19, 2026 (GLOBE NEWSWIRE) — Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local,…"
Eupraxia Pharmaceuticals Announces Voting Results from Annual General Meeting of Shareholders
financialpost.com
June 19, 2026 at 9:03 PM
📰 #Finance
"VANCOUVER, British Columbia, May 01, 2026 (GLOBE NEWSWIRE) — Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to…"
"VANCOUVER, British Columbia, May 01, 2026 (GLOBE NEWSWIRE) — Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to…"
Eupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officer
financialpost.com
May 1, 2026 at 10:30 PM